Teachers Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Teachers Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$100K	Buy	1,408 +246	+21%	+$15.6K	﹤0.01%	2934
2018 Q4	$93K	Hold	1,162	–	–	﹤0.01%	2962
2018 Q3	$542K	Sell	1,162 -7	-0.6%	-$2.81K	﹤0.01%	2601
2018 Q2	$465K	Buy	1,169 +459	+65%	+$163K	﹤0.01%	2685
2018 Q1	$217K	Hold	710	–	–	﹤0.01%	2862
2017 Q4	$209K	Hold	710	–	–	﹤0.01%	2913
2017 Q3	$389K	Hold	710	–	–	﹤0.01%	2699
2017 Q2	$423K	Buy	710 +530	+294%	+$234K	﹤0.01%	2676
2017 Q1	$77K	Hold	180	–	–	﹤0.01%	3004
2016 Q4	$93K	Hold	180	–	–	﹤0.01%	3014
2016 Q3	$77K	Buy	+180	New	+$70.3K	﹤0.01%	3026

Other funds holding RNAC

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Teachers Advisors's RNAC Position: Q1 2019 in Review

Teachers Advisors increased its Cartesian Therapeutics (RNAC) stake by 21% in Q1 2019, buying an estimated $15.6K and bringing the position to 1,408 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

Teachers Advisors first reported a position in RNAC in Q3 2016 and has held it in 11 quarters since. The position peaked at $542K in Q3 2018. 56 funds tracked by Wall St. Rank hold RNAC as of Q1 2019.

Teachers Advisors held 1,408 shares of Cartesian Therapeutics worth $100K as of Q1 2019.
Teachers Advisors bought 246 Cartesian Therapeutics shares in Q1 2019, an estimated $15.6K.
Cartesian Therapeutics made up ﹤0.01% of Teachers Advisors's portfolio in Q1 2019, its #2934 holding.
Teachers Advisors first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 11 quarters since.
Teachers Advisors's Cartesian Therapeutics position peaked at $542K in Q3 2018.
56 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.